Study of Serum Tumor Markers of HBV Associated HCC

Not yet recruiting

• Conditions: HCC
• Interventions: Diagnostic Test: tumor tissue and blood tests

• Registration Number: NCT05825196
• Lead Sponsor: Qianfoshan Hospital

Brief Summary

In this study, the investigators will detect the expression of four potential HBV-related HCC biomarkers: PGIR,FAM3C,LAMB1 and SDC4 in tumor tissues and peripheral blood, to explore the specific molecular markers for the early diagnosis of HBV-related HCC.

Detailed Description

Paired hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and adjacent liver tissues were selected, and the mRNA and protein expressions of the PGIR,FAM3C,LAMB1 and SDC4 biomarkers in tissues were detected by RT-PCR, western Blot and immunohistochemical analysis. At the same time, healthy subjects were selected as the control group, and mRNA and protein expression levels of the above molecules in blood were detected by RT-PCR and ELISA. At the same time, the correlation between the above biomarkers and the clinical data of patients, such as diagnosis, pathological grading, recurrence, metastasis and survival time was statistically analyzed.

Study Timeline

• Study First Submitted: 2023-03-26
• Status Verified: 2023-04
• Study First Submitted QC: 2023-04-10
• Last Update Submitted: 2023-04-10
• Study First Posted: 2023-04-24
• Last Update Posted: 2023-04-24
• Study Start: 2023-05-01
• Primary Completion: 2025-01-31
• Study Completion: 2025-12-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 164

Inclusion Criteria

• No local or systemic treatment was performed before surgery. The patients were finally diagnosed with HBV-related HCC by examination and imaging examination, and the clinicopathologic data were complete.

Exclusion Criteria

• Patients with benign liver diseases, such as hepatic cysts and hepatic hemangiomas, or have tumors other than HBV-related HCC.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
HBV-associated HCC group	tumor tissue and blood tests	The patient was finally diagnosed with HBV-related HCC by examination and imaging examination, and the clinicopathologic data were complete.
negative control group	tumor tissue and blood tests	HBV positive but not HCC
Healthy control group	tumor tissue and blood tests	Healthy crowd

Primary Outcome Measures

Name	Time	Method
Detection of RNA and protein for diagnosis	6 months	Detect the content of the RNA and protein in tumor and serum